Vegas-Revenga N, et al. - To estimate the efficiency and safety of tocilizumab (TCZ) in refractory cystoid macular edema (CME) (the leading cause of blindness), investigators assessed 25 candidates in this retrospective case series. They noticed the following ocular patterns: panuveitis (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermediate uveitis (n = 4). They observed a statistically significant improvement in macular thickness (415.7 ± 177.2 vs 259.1 ± 499.5 μm) and best-corrected visual acuity (BCVA) (0.39 ± 0.31 vs 0.54 ± 0.33) irrespective of the underlying disease. It supported the reduction of the daily dose of prednisone (15.9 ± 13.6 mg/day vs 3.1 ± 2.3 mg/day) after 12 months of therapy. They achieved remission in 14 candidates following administration of TCZ in refractory uveitis-related CME